Suppr超能文献

新型直型3F引导鞘用于经桡动脉途径血管内治疗的初步经验:可行性与安全性

Preliminary Experience With Novel Straight 3-Fr Guiding Sheath for Transradial Access in Endovascular Treatment: Feasibility and Safety.

作者信息

Fuga Michiyasu, Sano Tohru, Hataoka Shunsuke, Ishibashi Toshihiro, Kan Issei, Aoki Ken, Tachi Rintaro, Kato Naoki, Nagayama Gota, Murayama Yuichi

机构信息

Department of Neurosurgery, The Jikei University School of Medicine, Tokyo , Japan.

Department of Neurosurgery, The Jikei University School of Medicine, Katsushika Medical Center, Tokyo , Japan.

出版信息

Oper Neurosurg (Hagerstown). 2025 Mar 1;28(3):368-378. doi: 10.1227/ons.0000000000001307. Epub 2024 Aug 12.

Abstract

BACKGROUND AND OBJECTIVES

Radial artery diameter may limit whether a guiding sheath (GS) can be used via transradial artery access (TRA). A smaller GS may reduce the risk of access site-related complications. This study investigated the feasibility and safety of endovascular treatment (EVT) using a straight-shaped 3-Fr GS (Axcelguide; Medikit).

METHODS

Patients who underwent EVT with a straight-shaped 3-Fr GS at 3 institutions between April 2022 and March 2024 were retrospectively reviewed. Patient background, anatomic and procedural factors, and complications were recorded.

RESULTS

Twenty-six pathologies were treated with EVT using a 3-Fr GS. Median radial artery diameter was 1.9 mm, and distal TRA (73.1%) was selected more often than TRA (26.9%) as the access site. The breakdown of target pathologies and the role of the 3-Fr GS were as follows: 12 unruptured cerebral aneurysms for intra-aneurysmal coiling, with 5 dural arteriovenous fistulas, 5 brain or head and neck tumors, 2 chronic subdural hematoma, 1 arteriovenous malformation, and 1 hereditary hemorrhagic telangiectasia for transarterial embolization. A success rate of 96.2% was achieved, with no access site- or non-access site-related complications observed within 30 days.

CONCLUSION

The straight-shaped 3-Fr GS may be applicable for selected pathologies, allowing access even with RAs <2 mm in diameter and facilitating EVT without complications. Preliminary experience with the 3-Fr GS via TRA demonstrated excellent feasibility and safety.

摘要

背景与目的

桡动脉直径可能会限制是否能够经桡动脉途径(TRA)使用导引导管(GS)。较小的GS可能会降低与穿刺部位相关并发症的风险。本研究探讨了使用直型3F GS(Axcelguide;Medikit)进行血管内治疗(EVT)的可行性和安全性。

方法

回顾性分析了2022年4月至2024年3月期间在3家机构接受直型3F GS进行EVT的患者。记录患者背景、解剖和操作因素以及并发症。

结果

使用3F GS对26种病变进行了EVT治疗。桡动脉中位直径为1.9mm,作为穿刺部位,远端TRA(73.1%)的选择频率高于TRA(26.9%)。目标病变的分类及3F GS的作用如下:12例未破裂脑动脉瘤行瘤内栓塞,5例硬脑膜动静脉瘘,5例脑或头颈部肿瘤,2例慢性硬膜下血肿,1例动静脉畸形,1例遗传性出血性毛细血管扩张症行经动脉栓塞。成功率达到96.2%,30天内未观察到与穿刺部位或非穿刺部位相关的并发症。

结论

直型3F GS可能适用于特定病变,即使在直径<2mm的桡动脉情况下也能实现穿刺,并有助于无并发症地进行EVT。经TRA使用3F GS的初步经验显示出极佳的可行性和安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb21/11810025/cda95ddf8ba3/ons-28-368-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验